Healthcare provider profile · identity verified

Tonya M Carr, DO

Allopathic & Osteopathic Physicians|Internal Medicine · JOHNSON CITY, TN · NPI 1396988978

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Tonya M Carr, DO received $29.71 in general payments during 2025 across 1 reported records.

United Therapeutics Corporation accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$29.71

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
United Therapeutics Corporation Unresolved — no canonical attribution shown $29.71100.0%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$29.711

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Tyvaso
Normalized: tyvaso
Drug United Therapeutics Corporation $29.71 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
Levothyroxine SodiumLevothyroxine Sodium24524
EliquisApixaban18528
OmeprazoleOmeprazole17723
FurosemideFurosemide17053
Trazodone HclTrazodone Hcl15023
Atorvastatin CalciumAtorvastatin Calcium13316
Amlodipine BesylateAmlodipine Besylate12530
Metoprolol TartrateMetoprolol Tartrate12224
Metoprolol SuccinateMetoprolol Succinate12123
Quetiapine FumarateQuetiapine Fumarate12118
ClopidogrelClopidogrel Bisulfate11814
Potassium ChloridePotassium Chloride11022
LisinoprilLisinopril10730
Donepezil HclDonepezil Hcl10614
Pantoprazole SodiumPantoprazole Sodium9930
Tamsulosin HclTamsulosin Hcl9714
Duloxetine HclDuloxetine Hcl88suppressed
FamotidineFamotidine8811
Buspirone HclBuspirone Hcl84suppressed
Divalproex SodiumDivalproex Sodium78suppressed
Carbidopa-LevodopaCarbidopa/Levodopa77suppressed
Losartan PotassiumLosartan Potassium7514
Escitalopram OxalateEscitalopram Oxalate7012
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen7046
MethocarbamolMethocarbamol6920
Hydralazine HclHydralazine Hcl63suppressed
MirtazapineMirtazapine62suppressed
AtenololAtenolol59suppressed
CarvedilolCarvedilol58suppressed
AllopurinolAllopurinol55suppressed
AripiprazoleAripiprazole53suppressed
Fluoxetine HclFluoxetine Hcl53suppressed
Pravastatin SodiumPravastatin Sodium52suppressed
XareltoRivaroxaban46suppressed
CelecoxibCelecoxib43suppressed
GabapentinGabapentin4322
Ondansetron HclOndansetron Hcl4223
Oxybutynin ChlorideOxybutynin Chloride42suppressed
TradjentaLinagliptin42suppressed
LevetiracetamLevetiracetam41suppressed
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav4037
PrednisonePrednisone3725
Amiodarone HclAmiodarone Hcl36suppressed
Colestipol HclColestipol Hcl36suppressed
Divalproex Sodium ErDivalproex Sodium36suppressed
Oxybutynin Chloride ErOxybutynin Chloride3511
Ropinirole HclRopinirole Hcl35suppressed
SucralfateSucralfate35suppressed
Ondansetron OdtOndansetron3230
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen3231
Isosorbide Mononitrate ErIsosorbide Mononitrate30suppressed
Bupropion HclBupropion Hcl29suppressed
MeloxicamMeloxicam28suppressed
OlanzapineOlanzapine27suppressed
CephalexinCephalexin2622
GlipizideGlipizide26suppressed
Montelukast SodiumMontelukast Sodium25suppressed
Tizanidine HclTizanidine Hcl25suppressed
Memantine HclMemantine Hcl23suppressed
LamotrigineLamotrigine22suppressed
Doxycycline HyclateDoxycycline Hyclate2116
FluconazoleFluconazole2117
EntrestoSacubitril/Valsartan20suppressed
Naloxone HclNaloxone Hcl2020
Oxycodone HclOxycodone Hcl2018
Fluticasone PropionateFluticasone Propionate19suppressed
LorazepamLorazepam1914
CalcitriolCalcitriol18suppressed
Albuterol Sulfate HfaAlbuterol Sulfate1711
FinasterideFinasteride17suppressed
Metformin HclMetformin Hcl17suppressed
NystopNystatin17suppressed
AlprazolamAlprazolam15suppressed
Doxycycline MonohydrateDoxycycline Monohydrate1414
Hydroxyzine HclHydroxyzine Hcl14suppressed
Sertraline HclSertraline Hcl14suppressed
Kapspargo SprinkleMetoprolol Succinate13suppressed
LevofloxacinLevofloxacin1313
MethylprednisoloneMethylprednisolone13suppressed
NystatinNystatin13suppressed
TorsemideTorsemide13suppressed
LatanoprostLatanoprost12suppressed
MetolazoneMetolazone12suppressed
Sodium Chloride0.9 % Sodium Chloride12suppressed
AzithromycinAzithromycin11suppressed
DexamethasoneDexamethasone11suppressed
Dilt-XrDiltiazem Hcl11suppressed
Diltiazem HclDiltiazem Hcl11suppressed
Folic AcidFolic Acid11suppressed
Memantine Hcl ErMemantine Hcl11suppressed
Paroxetine HclParoxetine Hcl11suppressed
Rosuvastatin CalciumRosuvastatin Calcium11suppressed
SpironolactoneSpironolactone11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $29.71 · 1 records United Therapeutics Corporation Tyvaso
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error